Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review

Samiha Mohsen, Philip T. Sobash, Ghada Fahad Algwaiz, Noor Nasef, Safaa Abed Al-Zeidaneen, Nagla Abdel Karim

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt’s lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.

Original languageEnglish (US)
Pages (from-to)1695-1708
Number of pages14
JournalCurrent Oncology
Issue number3
StatePublished - Mar 2022
Externally publishedYes


  • Autophagy
  • Cancer
  • Chloroquine
  • Clinical trial
  • Hydroxychloroquine
  • Pevonedistat

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review'. Together they form a unique fingerprint.

Cite this